Retatrutide Knee Osteoarthritis Pain Relief Weight Loss Trial

The retatrutide knee osteoarthritis pain relief weight loss trial, called TRIUMPH-4, delivered groundbreaking Phase 3 results[1][2]. Patients on the highest dose lost 28.7% of their body weight on average—about 71 pounds[1]—while achieving a 75.8% drop in knee pain scores[1]. These findings highlight retatrutide's potential to tackle both obesity and osteoarthritis pain at once, offering hope for millions.

Introduction to the Retatrutide Knee Osteoarthritis Pain Relief Weight Loss Trial

The TRIUMPH-4 trial marks a key step in treating obesity linked to knee pain[2]. Sponsored by Eli Lilly, the retatrutide knee osteoarthritis pain relief weight loss trial tested retatrutide in people with overweight or obesity and knee osteoarthritis[1][2]. Topline results came out on December 11, 2025[1], showing strong benefits in weight loss and pain relief[1]. Eli Lilly press release.

What is Retatrutide? Triple Agonist Mechanism

Retatrutide, also known as LY3437943, is an investigational drug[2]. It acts as a triple agonist, targeting three hormones: GIP, GLP-1, and glucagon[4]. This combo helps control blood sugar, curb appetite, boost energy use, and reduce fat.

Unlike dual agonists like tirzepatide, the glucagon part may add extra fat-burning power[4]. Patients get it as a weekly shot under the skin[2]. Early trials showed up to 24% weight loss in 48 weeks[4], setting high hopes for the retatrutide knee osteoarthritis pain relief weight loss trial in Phase 3. Learn more about GLP-1 agonists for obesity.

Why Focus on Knee Osteoarthritis and Obesity?

Obesity worsens knee osteoarthritis (OA) by adding stress to joints. Extra weight causes inflammation and pain, making daily tasks hard. About 84% of TRIUMPH-4 participants had BMI over 35[1][2], a group at high risk.

Treating both issues together could break the cycle. Weight loss unloads joints, easing pain mechanically. Retatrutide aims to deliver this dual punch for better outcomes. See the trial details on ClinicalTrials.gov (NCT05931367)[2].

Overview of TRIUMPH-4 Trial (NCT05931367)

TRIUMPH-4 is a Phase 3 study with 445 adults[1][2]. It ran about 68-77 weeks across global sites[2]. All met American College of Rheumatology (ACR) standards for knee OA and had BMI ≥27 without diabetes[2].

Everyone followed diet and exercise plans. The trial used the WOMAC scale to measure pain, stiffness, and function[1][2]. It was the first Phase 3 obesity drug study focused on knee OA patients[1].

TRIUMPH-4 Trial Design and Participant Profile

This trial used a strict setup to ensure reliable results. It was randomized, double-blind, and placebo-controlled[2]. Participants got either retatrutide or a dummy shot, with neither knowing which. The retatrutide knee osteoarthritis pain relief weight loss trial design prioritized real-world relevance for obese OA patients[2].

Study Design: Randomized, Double-Blind, Placebo-Controlled

Patients were split 1:1:1 into three groups: 9 mg retatrutide, 12 mg retatrutide, or placebo[2]. Doses started low and ramped up to reduce side effects[2]. The main check was at 68 weeks, with some followed to 77 weeks[2].

• Lifestyle coaching was standard for all groups.
• This design tests if retatrutide works beyond diet alone.
• It followed good clinical practice standards worldwide.

Eligibility Criteria: BMI ≥27, Knee OA per ACR Standards

To join, adults needed BMI ≥27 kg/m² and moderate-to-severe knee OA by ACR rules[2]. No diabetes allowed. Exclusions included recent big weight changes, knee surgery, injections, or other joint issues[2].

• No prior weight loss drugs or bariatric plans.
• This focused on real-world patients with obesity-driven knee pain.
• Baseline scans confirmed OA changes. Explore knee OA treatments overview.

Doses Tested: 9 mg vs 12 mg Weekly Subcutaneous Injections

Both doses were weekly skin shots[2]. The 12 mg was the top dose tested[2]. Titration took weeks to build tolerance.

Placebo mimicked the shots. All groups got nutrition and exercise tips.

Sample Size, Duration, and Global Scope (445 Participants, 68-77 Weeks)

445 people joined from many countries[2]. About 84% had BMI ≥35[1][2]. The core phase hit 68 weeks for key measures[2].

This size gives solid stats power. Global reach ensures diverse results. Full data is pending peer review.

Efficacy Results: Weight Loss and Pain Relief Breakthroughs

TRIUMPH-4 hit all main goals[1]. Both doses beat placebo on weight and pain[1]. Improvements held across analysis methods[1]. The retatrutide knee osteoarthritis pain relief weight loss trial efficacy results stunned experts with their scale[1].

Co-Primary Endpoint: 28.7% Average Weight Loss (71.2 lbs at 12 mg)

At 12 mg, mean weight drop was 28.7% or 71.2 pounds[1]. The 9 mg group lost 26.4%[1]. Placebo saw just 2.1%[1].

This beats many drugs. Weight loss aids joints by cutting load. Stats showed high significance (p<0.001)[1].

Dose	Weight Loss (%)	Absolute (lbs)
12 mg	28.7	71.2
9 mg	26.4	~65
Placebo	2.1	~5

WOMAC Pain Subscale: 4.5-Point Reduction (75.8% Improvement)

WOMAC measures OA pain on a 0-20 scale (higher is worse)[1]. Retatrutide cut scores by up to 4.5 points—75.8% better[1]. Over two-thirds hit 70%+ relief[1].

More than 1 in 8 (12-14%) were pain-free vs. 4% on placebo[1]. Check detailed WOMAC pain reduction mechanism in TRIUMPH-4 for deeper insights on WOMAC pain reduction.

Pain Freedom Rates: >1 in 8 Patients Completely Pain-Free

Full pain relief means WOMAC pain score of 0[1]. Retatrutide doubled or tripled rates vs. placebo[1]. This changes lives for severe cases.

Gains built over time, linked to weight drop.

Physical Function Enhancements and All Endpoints Met

Function scores (WOMAC) improved too[1]. Patients moved better, less stiff[1]. All primary and key secondary endpoints succeeded for both doses[1].

• Pain, weight, and daily life metrics all improved.
• Efficacy held under different statistical views (estimands)[1].

Safety Data and Side Effects from the Trial

Safety matched other incretin drugs like GLP-1s[1]. Most issues were mild to moderate[1]. Full details await publication[1]. In the retatrutide knee osteoarthritis pain relief weight loss trial safety data, no surprises emerged[1].

Overall Safety Profile Consistent with Incretin Class

No new red flags[1]. GI effects are typical: nausea, vomiting, diarrhea[1]. Rates were dose-related but dropped over time[1].

Heart and other checks were fine in topline[1].

Common Side Effects: GI Issues and Dysesthesia (~20.9%)

GI problems hit early, mostly mild[1]. Dysesthesia—a skin tingling sensation—affected about 20.9% at high dose[1]. Learn strategies to manage retatrutide dysesthesia.

No major vision or thyroid issues noted[1].

Discontinuation Rates and BMI Correlations

Dropouts were low, similar to class[1]. Higher BMI linked to slightly more quits, but manageable[1]. See Phase 3 safety profile and BMI-related discontinuations.

Most stayed through 68 weeks[1].

Limitations: Topline Data Pending Full Results

Topline lacks full adverse event tables[1]. Long-term data is limited[1]. Not for diabetics here[2].

Regulatory Status: FDA Approval and Legal Outlook

Retatrutide is investigational only[3]. No approvals yet as of 2026[3]. The retatrutide knee osteoarthritis pain relief weight loss trial supports future filings[1].

Current Status: Investigational, No FDA Approval (as of 2026)

Phase 3 success boosts chances[1]. But FDA review needs full data[3]. Knee OA is a new angle[1].

Path to Approval: NDA Submission and PDUFA Timeline

Eli Lilly plans NDA soon[1]. Track the retatrutide NDA submission and FDA PDUFA timeline. Obesity approval could come first[3]. FDA drug approval process[3].

OA label may follow.

Comparison of Legal Status Across Indications

Obesity trials lead[3]. OA is supportive data[1]. Tirzepatide (Zepbound) is approved for weight, seeking OA[3].

How Retatrutide Compares to Tirzepatide in Knee OA Trials

Retatrutide edges out in weight loss[1]. Both ease OA pain[1]. In the retatrutide knee osteoarthritis pain relief weight loss trial vs. tirzepatide comparisons, triple action shines[1].

Head-to-Head: Weight Loss (28.7% vs ~20%) and Pain Relief

TRIUMPH-4: 28.7% vs. SURMOUNT-OA tirzepatide ~20%[1]. Pain drops similar but retatrutide higher[1]. Read retatrutide vs tirzepatide for non-diabetic weight loss.

Non-diabetics benefit most[1].

Key Differences: Triple vs Dual Agonist Mechanism

Extra glucagon boosts liver fat burn[4]. Better for stubborn obesity[4].

SURMOUNT-OA vs TRIUMPH-4 Insights

Both placebo-controlled[1]. Retatrutide first to nail OA as primary in obesity trial[1].

• SURMOUNT-OA focused on tirzepatide in similar group[1].
• Retatrutide shows superior weight loss edge[1].

Broader TRIUMPH Program and Future Milestones

TRIUMPH covers obesity complications[1]. Over 5,800 in Phase 3[1]. The retatrutide knee osteoarthritis pain relief weight loss trial fits this big push[1].

TRIUMPH-1, TRIUMPH-2, TRIUMPH-3: Related Trials Overview

TRIUMPH-1/2: general obesity, OSA subsets[1]. TRIUMPH-3: heart patients[1]. See TRIUMPH-3 cardiovascular outcomes.

Nested designs speed things[1].

Upcoming Readouts: 7 More Phase 3 Trials in 2026

Diabetes, liver, more obesity data coming[1]. Full TRIUMPH-4 soon[1].

• 2026 brings key milestones[1].
• Builds case for broad approvals[1].

Potential Impact for Obesity, OSA, and Knee OA Patients

Could treat root causes[1]. Lilly: "Important option for complications like knee OA."[1]

Implications and Next Steps for Patients

Best for obese knee OA folks. Talk to doctors. The retatrutide knee osteoarthritis pain relief weight loss trial implications point to combined therapy wins[1].

Who Might Benefit: Obesity + Moderate-to-Severe Knee OA

• BMI ≥27, ACR OA, no diabetes[2].
• Weight loss plus pain relief combo[1].

Exclusion Criteria and Lifestyle Adjuncts

• No recent drugs/surgery[2].
• Diet/exercise key always[2].

What to Watch: Full Results and Approval Prospects

Peer-reviewed papers, FDA news[3]. Stay tuned via ClinicalTrials.gov[2].

Conclusion: A Game-Changer for Knee OA Pain Relief?

The retatrutide knee osteoarthritis pain relief weight loss trial, TRIUMPH-4, sets a new standard in Phase 3 research[1][2]. With 28.7% average weight loss at the 12 mg dose and a remarkable 75.8% WOMAC pain reduction[1], it met all endpoints in 445 participants[1][2]. Over 1 in 8 patients achieved complete pain freedom, far surpassing placebo[1], while physical function soared[1].

This dual benefit—massive weight reduction unloading knee joints plus potential anti-inflammatory effects—could transform lives for those with obesity and moderate-to-severe knee OA[1]. Safety aligned with incretin therapies, with manageable GI issues and dysesthesia[1]. Though full data and FDA review are pending[1][3], the topline success across the TRIUMPH program signals retatrutide's promise[1].

Patients with BMI ≥27 and ACR-defined knee OA should discuss options with providers, especially alongside lifestyle changes[2]. Watch for 2026 readouts from seven more trials and NDA filings[1]. Retatrutide may soon offer a powerful tool against obesity's joint toll[1]. Consult healthcare pros for personalized advice—this isn't medical guidance. The retatrutide knee osteoarthritis pain relief weight loss trial takeaways: hope on the horizon for better pain-free mobility[1].

References

1. Eli Lilly Press Release: TRIUMPH-4 Topline Results (Dec 11, 2025)
2. ClinicalTrials.gov: TRIUMPH-4 Trial (NCT05931367)
3. FDA: Drug Development and Approval Process
4. NEJM: Phase 2 Trial of Retatrutide for Obesity